Logo image of NARI

INARI MEDICAL INC (NARI) Stock Fundamental Analysis

NASDAQ:NARI - Nasdaq - US45332Y1091 - Common Stock - Currency: USD

79.97  +0.04 (+0.05%)

After market: 79.98 +0.01 (+0.01%)

Fundamental Rating

4

Taking everything into account, NARI scores 4 out of 10 in our fundamental rating. NARI was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of NARI is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NARI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year NARI has reported negative net income.
NARI had a positive operating cash flow in the past year.
In multiple years NARI reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: NARI reported negative operating cash flow in multiple years.
NARI Yearly Net Income VS EBIT VS OCF VS FCFNARI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M

1.2 Ratios

NARI has a Return On Assets (-11.27%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -18.07%, NARI is in the better half of the industry, outperforming 61.17% of the companies in the same industry.
Industry RankSector Rank
ROA -11.27%
ROE -18.07%
ROIC N/A
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
NARI Yearly ROA, ROE, ROICNARI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

NARI has a Gross Margin of 86.82%. This is amongst the best in the industry. NARI outperforms 97.34% of its industry peers.
NARI's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for NARI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
NARI Yearly Profit, Operating, Gross MarginsNARI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

NARI does not have a ROIC to compare to the WACC, probably because it is not profitable.
NARI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NARI has more shares outstanding
There is no outstanding debt for NARI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NARI Yearly Shares OutstandingNARI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
NARI Yearly Total Debt VS Total AssetsNARI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

NARI has an Altman-Z score of 11.25. This indicates that NARI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of NARI (11.25) is better than 89.36% of its industry peers.
NARI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.25
ROIC/WACCN/A
WACC9.06%
NARI Yearly LT Debt VS Equity VS FCFNARI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

NARI has a Current Ratio of 1.77. This is a normal value and indicates that NARI is financially healthy and should not expect problems in meeting its short term obligations.
NARI has a Current ratio of 1.77. This is in the lower half of the industry: NARI underperforms 70.74% of its industry peers.
NARI has a Quick Ratio of 1.40. This is a normal value and indicates that NARI is financially healthy and should not expect problems in meeting its short term obligations.
NARI has a worse Quick ratio (1.40) than 63.30% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.4
NARI Yearly Current Assets VS Current LiabilitesNARI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

NARI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1183.33%.
NARI shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.39%.
Measured over the past years, NARI shows a very strong growth in Revenue. The Revenue has been growing by 135.60% on average per year.
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Sales Q2Q%21.39%

3.2 Future

NARI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 121.24% yearly.
NARI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.44% yearly.
EPS Next Y-2492.94%
EPS Next 2Y192.8%
EPS Next 3Y191.18%
EPS Next 5Y121.24%
Revenue Next Year22.24%
Revenue Next 2Y20.1%
Revenue Next 3Y18.92%
Revenue Next 5Y17.44%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NARI Yearly Revenue VS EstimatesNARI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NARI Yearly EPS VS EstimatesNARI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

NARI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
NARI is valuated quite expensively with a Price/Forward Earnings ratio of 405.53.
Based on the Price/Forward Earnings ratio, NARI is valued a bit cheaper than the industry average as 64.89% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of NARI to the average of the S&P500 Index (22.68), we can say NARI is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 405.53
NARI Price Earnings VS Forward Price EarningsNARI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 200 300 400

4.2 Price Multiples

67.02% of the companies in the same industry are more expensive than NARI, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2971.47
EV/EBITDA N/A
NARI Per share dataNARI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as NARI's earnings are expected to grow with 191.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y192.8%
EPS Next 3Y191.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NARI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INARI MEDICAL INC

NASDAQ:NARI (2/18/2025, 8:00:58 PM)

After market: 79.98 +0.01 (+0.01%)

79.97

+0.04 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-28 2024-10-28/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners95.33%
Inst Owner Change-1.4%
Ins Owners3.81%
Ins Owner Change-1.15%
Market Cap4.68B
Analysts77.27
Price Target76.99 (-3.73%)
Short Float %4.66%
Short Ratio0.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-61.42%
Min EPS beat(2)-154%
Max EPS beat(2)31.16%
EPS beat(4)1
Avg EPS beat(4)-384.45%
Min EPS beat(4)-1407.19%
Max EPS beat(4)31.16%
EPS beat(8)5
Avg EPS beat(8)-35.38%
EPS beat(12)8
Avg EPS beat(12)-18.85%
EPS beat(16)11
Avg EPS beat(16)50.45%
Revenue beat(2)0
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-0.55%
Max Revenue beat(2)-0.19%
Revenue beat(4)1
Avg Revenue beat(4)-0.25%
Min Revenue beat(4)-1.73%
Max Revenue beat(4)1.46%
Revenue beat(8)5
Avg Revenue beat(8)0.59%
Revenue beat(12)9
Avg Revenue beat(12)1.56%
Revenue beat(16)13
Avg Revenue beat(16)3.41%
PT rev (1m)12.89%
PT rev (3m)17.02%
EPS NQ rev (1m)250.29%
EPS NQ rev (3m)250.29%
EPS NY rev (1m)-2.57%
EPS NY rev (3m)-2.25%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 405.53
P/S 8.15
P/FCF 2971.47
P/OCF 330.4
P/B 10.77
P/tB 60.34
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)0.2
Fwd EY0.25%
FCF(TTM)0.03
FCFY0.03%
OCF(TTM)0.24
OCFY0.3%
SpS9.81
BVpS7.42
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.27%
ROE -18.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.82%
FCFM 0.27%
ROA(3y)-0.97%
ROA(5y)0.17%
ROE(3y)-1.09%
ROE(5y)-0.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.99%
GM growth 5Y1.71%
F-Score3
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 86.41%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.4
Altman-Z 11.25
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)251.19%
Cap/Depr(5y)332.22%
Cap/Sales(3y)2.93%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1183.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-280%
EPS Next Y-2492.94%
EPS Next 2Y192.8%
EPS Next 3Y191.18%
EPS Next 5Y121.24%
Revenue 1Y (TTM)22.39%
Revenue growth 3Y52.31%
Revenue growth 5Y135.6%
Sales Q2Q%21.39%
Revenue Next Year22.24%
Revenue Next 2Y20.1%
Revenue Next 3Y18.92%
Revenue Next 5Y17.44%
EBIT growth 1Y-352.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-278.61%
EBIT Next 3Y107.8%
EBIT Next 5YN/A
FCF growth 1Y107.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y238.69%
OCF growth 3Y165.95%
OCF growth 5YN/A